𝔖 Bobbio Scriptorium
✦   LIBER   ✦

The von Hippel-Lindau tumor suppressor gene expression level has prognostic value in neuroblastoma

✍ Scribed by Jasmien Hoebeeck; Jo Vandesompele; Helén Nilsson; Katleen De Preter; Nadine Van Roy; Els De Smet; Nurten Yigit; Anne De Paepe; Geneviève Laureys; Sven Påhlman; Frank Speleman


Publisher
John Wiley and Sons
Year
2006
Tongue
French
Weight
166 KB
Volume
119
Category
Article
ISSN
0020-7136

No coin nor oath required. For personal study only.

✦ Synopsis


Abstract

Deletions of the short arm of chromosome 3 are often observed in a specific subset of aggressive neuroblastomas (NBs) with loss of distal 11q and without MYCN amplification. The critical deleted region encompasses the locus of the von Hippel‐Lindau gene (VHL, 3p25). Constitutional loss of function mutations in the VHL gene are responsible for the VHL syndrome, a dominantly inherited familial cancer syndrome predisposing to a variety of neoplasms, including pheochromocytoma. Pheochromocytomas are, like NB, derived from neural crest cells, but, unlike NB, consist of more mature chromaffin cells instead of immature neuroblasts. Further arguments for a putative role of VHL in NB are its function as oxygen sensitizer and the reported relation between hypoxia and dedifferentiation of NB cells, leading to a more aggressive phenotype. To test the possible involvement of VHL in NB, we did mRNA expression analysis and sought evidence for VHL gene inactivation. Although no evidence for a classic tumor suppressor role for VHL in NB could be obtained, a strong correlation was observed between reduced levels of VHL mRNA and low patient survival probability (p = 0.013). Furthermore, VHL appears to have predictive power in NTRK1 (TRKA) positive tumor samples with presumed favorable prognosis, which makes it a potentially valuable marker for more accurate risk assessment in this subgroup of patients. The significance of the reduced VHL expression levels in relation to NB tumor biology remains unexplained, as functional analysis demonstrated no clear effect of the reduction in VHL mRNA expression on protein stability of its downstream target hypoxia‐inducible factor α. © 2006 Wiley‐Liss, Inc.


📜 SIMILAR VOLUMES


Induction of the von Hippel-Lindau tumor
✍ Jörn Karhausen; Tianqing Kong; Sailaja Narravula; Sean P. Colgan 📂 Article 📅 2005 🏛 John Wiley and Sons 🌐 English ⚖ 251 KB

## Abstract Hypoxia–inducible factor (HIF) remains the central focus of oxygen sensing during hypoxia. HIF is a heterodimeric transcription factor consisting of an oxygen‐regulated alpha‐ and a constitutively expressed beta subunit. The von Hippel‐Lindau tumor suppressor (pVHL) is a component of th

Improved detection of germline mutations
✍ Catherine Stolle; Gladys Glenn; Berton Zbar; Jeffrey S. Humphrey; Peter Choyke; 📂 Article 📅 1998 🏛 John Wiley and Sons 🌐 English ⚖ 201 KB 👁 2 views

Communicated by Victor A. McKusick von Hippel-Lindau disease (VHL) is an inherited neoplastic disorder characterized by the development of tumors in the eyes, brain, spinal cord, inner ear, adrenal gland, pancreas, kidney, and epididymis. The VHL tumor suppressor gene was identified in 1993. Initial